Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
SIRT3
|
---|---|
ln Vitro |
5-Heptadecylresorcinol boosts SIRT3 in HUVECs [1] to reduce mitochondrial dysfunction at 0, 0.5, 1, and 2 µM during a 24-hour period. 5-Heptadecylresorcinol reduces mitochondrial damage and adipocyte lipolysis brought on by inflammatory conditioned medium (CM), while also reducing the generation of reactive oxygen species inside the mitochondria and the depolarization of the mitochondrial membrane [2]. By decreasing the release of glycerol from 3T3-L1 adipocytes, 5-Heptadecylresorcinol (5, 10 and 15 μM; 24 hours) significantly inhibits CM-induced lipolysis in adipocytes [2]. 5-Adipocytes with CM-induced mitochondrial dysfunction are improved by 5-Heptadecylresorcinol (5, 10 and 15 μM; 24 hours) [2].
|
ln Vivo |
5-Heptadecylresorcinol (30 mg/kg, 150 mg/kg; taken orally daily for 16 weeks) enhances lipid metabolism in mice fed a high-fat diet that are ApoE−/− [1]. 5-Heptadecylresorcinol improves body weight and decreases mitochondrial dysfunction and adipose tissue macrophage infiltration in mice when given orally every day for 16 weeks (30 mg/kg, 150 mg/kg) [2].
|
Cell Assay |
Western Blot Analysis[2]
Cell Types: 3T3-L1 adipocytes Tested Concentrations: 5, 10 and 15 μM Incubation Duration: 24 hrs (hours) Experimental Results: Increased the expression of UCP1, COX IV, PGC-1α, DRP1 and MFN2 proteins. |
Animal Protocol |
Animal/Disease Models: C57BL/6J mice[1][2]
Doses: 30 mg/kg, 150 mg/kg Route of Administration: PO; daily for 16 weeks Experimental Results: Lowered serum total cholesterol, triglyceride, VLDL-C, and LDL-C levels[1]. diminished adipose tissue macrophage infiltration from high-fat diet induced obese C57BL/6J mice[2]. |
References |
[1]. Rakshit D, et al. The Pharmacological Activity of Garlic (Allium sativum) in Parkinson's Disease: From Molecular Mechanisms to the Therapeutic Potential. ACS Chem Neurosci. 2023 Mar 15;14(6):1033-1044.
[2]. Yoo DY, et al. Neuroprotective effects of Z-ajoene, an organosulfur compound derived from oil-macerated garlic, in the gerbil hippocampal CA1 region after transient forebrain ischemia. Food Chem Toxicol. 2014 Oct;72:1-7. |
Molecular Formula |
C23H40O2
|
---|---|
Molecular Weight |
348.56
|
CAS # |
41442-57-3
|
SMILES |
C(C1=CC(O)=CC(O)=C1)CCCCCCCCCCCCCCCC
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8689 mL | 14.3447 mL | 28.6895 mL | |
5 mM | 0.5738 mL | 2.8689 mL | 5.7379 mL | |
10 mM | 0.2869 mL | 1.4345 mL | 2.8689 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.